search
Back to results

Chronic Total Occlusion Crossing With the Wildcat Catheter (CONNECT)

Primary Purpose

Peripheral Arterial Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer
Sponsored by
Avinger, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Peripheral Arterial Disease focused on measuring Chronic Total Occlusions, Superficial Femoral Artery, Popliteal Artery

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient is willing and able to provide informed consent.
  2. Patient is willing and able to comply with the study protocol.
  3. Patient is > 18 years old.
  4. Patient has peripheral arterial disease requiring revascularization as evidenced by contrast, CT or MR angiography.
  5. Patient has an occluded femoropopliteal artery that is 99-100% stenosed and is ≥ 1 cm and ≤ 30 cm in length by visual estimate.
  6. Target femoropopliteal vessel is ≥ 3.0 mm in diameter.
  7. Patient has Rutherford Classification of 2-5.

Exclusion Criteria:

  1. Patient has a known sensitivity or allergy to contrast materials that cannot be adequately pre-treated.
  2. Patient has a known sensitivity or allergy to anti-platelet medications.
  3. Patient is pregnant or lactating.
  4. Patient has a co-existing disease or medical condition contraindicating percutaneous intervention.
  5. Target vessel is severely calcified as evidenced by angiography.
  6. Target lesion is in a bypass graft.
  7. Target lesion is in a stent (i.e., in-stent restenosis).
  8. Patient has had a procedure on the target limb within 7 days.
  9. Patient has had a procedure on the target limb within the past 30 days and is unstable.
  10. Patient is simultaneously participating in an investigational device or drug study.
  11. Patient has a planned surgical or interventional procedure within 30 days after the study procedure.

Sites / Locations

  • Birmingham Heart Clinic
  • Arizona Regional / Adventis
  • Phoenix Heart Center
  • Sutter Memorial
  • Sharp Memorial
  • Coastal Vascular
  • Emory University Hospital
  • Detroit Medical Center
  • St. John Hospital and Medical Center
  • Central Michigan Community Hospital
  • St. Louis University
  • Jobst Vascular Center
  • Austin Heart
  • Cardiology Care Consultants
  • El Paso Cardiology Associates

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment

Arm Description

The Wildcat catheter is a CTO crossing catheter. Subjects will be subjected to crossing with this device.

Outcomes

Primary Outcome Measures

Major Adverse Events
The primary safety endpoint of the CONNECT Study was defined as absence of in-hospital or 30-days Major Adverse Events (MAEs), no evidence of clinically significant perforations, clinically significant embolizations or Grade C or greater dissections after Wildcat CTO crossing confirmed by angiography.
CTO Crossing Success Using the Wildcat
Successful femoropopliteal CTO crossing using the Wildcat identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography.

Secondary Outcome Measures

Full Information

First Posted
August 2, 2010
Last Updated
July 14, 2020
Sponsor
Avinger, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01174784
Brief Title
Chronic Total Occlusion Crossing With the Wildcat Catheter
Acronym
CONNECT
Official Title
A Non-randomized Study of the Avinger Wildcat Used to Cross Femoropopliteal CTOs
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
April 2011 (Actual)
Study Completion Date
June 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Avinger, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a prospective, multi-center, non-randomized study of the Wildcat Catheter to cross a single femoropopliteal chronic total occlusion (CTO). Safety and efficacy will be evaluated during the index procedure through 30-day follow-up.
Detailed Description
Patients with a CTO, defined as 99% to 100% stenosis of a peripheral artery, will be approached for enrollment in the study. Following providing informed consent, the CTO will be addressed by the Wildcat catheter, which will provide a route for the advancement of guidewires and other tools beyond the CTO. Data will be collected to assess the safety efficacy of use of the device during the procedure and up to 30 days post-procedure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease
Keywords
Chronic Total Occlusions, Superficial Femoral Artery, Popliteal Artery

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
88 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
The Wildcat catheter is a CTO crossing catheter. Subjects will be subjected to crossing with this device.
Intervention Type
Device
Intervention Name(s)
Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer
Other Intervention Name(s)
CONNECT
Intervention Description
A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
Primary Outcome Measure Information:
Title
Major Adverse Events
Description
The primary safety endpoint of the CONNECT Study was defined as absence of in-hospital or 30-days Major Adverse Events (MAEs), no evidence of clinically significant perforations, clinically significant embolizations or Grade C or greater dissections after Wildcat CTO crossing confirmed by angiography.
Time Frame
Index through 30-Day Follow-Up
Title
CTO Crossing Success Using the Wildcat
Description
Successful femoropopliteal CTO crossing using the Wildcat identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography.
Time Frame
Index through 30-Day Follow-Up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is willing and able to provide informed consent. Patient is willing and able to comply with the study protocol. Patient is > 18 years old. Patient has peripheral arterial disease requiring revascularization as evidenced by contrast, CT or MR angiography. Patient has an occluded femoropopliteal artery that is 99-100% stenosed and is ≥ 1 cm and ≤ 30 cm in length by visual estimate. Target femoropopliteal vessel is ≥ 3.0 mm in diameter. Patient has Rutherford Classification of 2-5. Exclusion Criteria: Patient has a known sensitivity or allergy to contrast materials that cannot be adequately pre-treated. Patient has a known sensitivity or allergy to anti-platelet medications. Patient is pregnant or lactating. Patient has a co-existing disease or medical condition contraindicating percutaneous intervention. Target vessel is severely calcified as evidenced by angiography. Target lesion is in a bypass graft. Target lesion is in a stent (i.e., in-stent restenosis). Patient has had a procedure on the target limb within 7 days. Patient has had a procedure on the target limb within the past 30 days and is unstable. Patient is simultaneously participating in an investigational device or drug study. Patient has a planned surgical or interventional procedure within 30 days after the study procedure.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tom Davis, MD
Organizational Affiliation
St. John Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Laiq Raja, MD
Organizational Affiliation
El Paso Cardiology Associates
Official's Role
Principal Investigator
Facility Information:
Facility Name
Birmingham Heart Clinic
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35235
Country
United States
Facility Name
Arizona Regional / Adventis
City
Mesa
State/Province
Arizona
ZIP/Postal Code
85206
Country
United States
Facility Name
Phoenix Heart Center
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
Sutter Memorial
City
Sacramento
State/Province
California
ZIP/Postal Code
95619
Country
United States
Facility Name
Sharp Memorial
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Coastal Vascular
City
Pensacola
State/Province
Florida
ZIP/Postal Code
32501
Country
United States
Facility Name
Emory University Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30308
Country
United States
Facility Name
Detroit Medical Center
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
St. John Hospital and Medical Center
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48236
Country
United States
Facility Name
Central Michigan Community Hospital
City
Mount Pleasant
State/Province
Michigan
ZIP/Postal Code
48858
Country
United States
Facility Name
St. Louis University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Jobst Vascular Center
City
Toledo
State/Province
Ohio
ZIP/Postal Code
43606
Country
United States
Facility Name
Austin Heart
City
Austin
State/Province
Texas
ZIP/Postal Code
78756
Country
United States
Facility Name
Cardiology Care Consultants
City
El Paso
State/Province
Texas
ZIP/Postal Code
79902
Country
United States
Facility Name
El Paso Cardiology Associates
City
El Paso
State/Province
Texas
ZIP/Postal Code
79902
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Chronic Total Occlusion Crossing With the Wildcat Catheter

We'll reach out to this number within 24 hrs